Literature DB >> 371879

Possible C1q bypass loop activation in the haemolytic uraemic syndrome.

L Nolin, S O'Regan, M Pelletier, G E Rivard, J G Mongeau, P Robitaille.   

Abstract

Ultrastructural and immunofluorescent microscopic studies were performed on renal tissue obtained from nine patients during the acute and convalescent phase of the haemolytic uraemic syndrome (HUS). All had glomerular deposits of IgM in the absence of circulating immune complexes. This was associated with deposition of C1q during the acute phase, and properdin and C3 during the convalescent phase. C4 was consistently absent. Since such a pattern of complement deposition does not fulfil criteria either for alternate or classical pathway activation, the possibility of C1q bypass loop activation by IgM is suggested.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371879      PMCID: PMC1537596     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

3.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

4.  A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway.

Authors:  J E May; M M Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

5.  Selective enzyme purification by affinity chromatography.

Authors:  P Cuatrecasas; M Wilchek; C B Anfinsen
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

Review 6.  The hemolytic uremic syndrome.

Authors:  B S Kaplan; P D Thomson; J P de Chadarévian
Journal:  Pediatr Clin North Am       Date:  1976-11       Impact factor: 3.278

7.  Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome.

Authors:  P J Klein; M Bulla; R A Newman; P Müller; G Uhlenbruck; H E Schaefer; G Krüger; R Fisher
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

8.  Hemolytic-uremic syndrome: absence of circulating endotoxin.

Authors:  P M van Wieringen; L A Monnens; J A Bakkeren
Journal:  Pediatrics       Date:  1976-10       Impact factor: 7.124

9.  Persistent glomerulonephritis following the haemolytic-uremic syndrome. Immunopathological and morphological studies.

Authors:  P M Cossio; R P Laguens; D J Pantin; M M de Bracco; F Molinas; L E Voyer; R M Arana
Journal:  Clin Exp Immunol       Date:  1977-09       Impact factor: 4.330

10.  Breakdown products of C3 and factor B in hemolytic-uremic syndrome.

Authors:  Y Kim; K Miller; A F Michael
Journal:  J Lab Clin Med       Date:  1977-04
View more
  3 in total

1.  Bypassing complement: evolutionary lessons and future implications.

Authors:  John P Atkinson; Michael M Frank
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

2.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

3.  The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells.

Authors:  Joyce Geelen; Maartje van den Biggelaar; Peter Linssen; Thea van der Velden; Koen Mertens; Leo Monnens
Journal:  Nephron Extra       Date:  2014-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.